NEW YORK, December 30, 2025, 2:30 PM ET — Regular session
- Catalyst Pharmaceuticals shares fell about 3% in afternoon trade, extending a two-day slide.
- Biotech ETFs were down more than the broader market in thin year-end trading.
- Investors are watching for the Federal Reserve’s meeting minutes later Tuesday and Catalyst’s next public update in January.
Shares of Catalyst Pharmaceuticals, Inc. fell 3.0% to $23.33 in afternoon trading on Tuesday. The stock has traded between $23.30 and $24.10 so far in the session.
The drop matters because trading can get choppy in the final days of the year, when fewer investors are active and price moves can be exaggerated. Mid-cap healthcare names often swing more than the major indexes in that setting.
Catalyst fell 1.2% on Monday to close at $24.06, according to MarketWatch data, and it remains well below its June 9 52-week high of $26.58. At Tuesday’s price, the stock is about 12% below that peak. MarketWatch
Biotech broadly lagged, with the iShares Nasdaq Biotechnology ETF down about 1.2% and the SPDR S&P Biotech ETF off roughly 1.5%.
U.S. stocks were mostly subdued in holiday-thin trading, and investors were waiting for the Federal Reserve’s meeting minutes later in the day. “It’s just a healthy rebalancing of allocations,” said Mark Hackett, chief market strategist at Nationwide, describing the broader repositioning in markets. MarketScreener
Catalyst’s valuation has been tied to execution in rare-disease drugs, and the company’s most recent results underscored that focus. In November, Catalyst reported third-quarter revenue of $148.4 million, raised its full-year 2025 revenue forecast to $565 million to $585 million, and highlighted a board-approved share repurchase program of up to $200 million through the end of 2026. GlobeNewswire
The company sells Firdapse and Agamree, and it has also been managing a decline in Fycompa revenue following the entry of generic tablet competition. Investors have been watching whether Agamree continues to gain traction at Duchenne muscular dystrophy centers as the launch matures.
Catalyst’s next scheduled public appearance is at the J.P. Morgan Healthcare Conference on Jan. 12, 2026, according to a company announcement. Traders often use those conference presentations to gauge prescription trends, pipeline talk and capital allocation plans. GlobeNewswire
On Wall Street, analyst sentiment remains broadly positive. MarketBeat data showed a “Buy” consensus rating, with an average 12-month price target of $32.67, implying about 40% upside from Tuesday’s trading level. MarketBeat
The next earnings catalyst is likely still weeks away. Zacks’ earnings calendar expects Catalyst’s next report around Feb. 25, 2026, though companies can shift dates. Zacks
In the near term, traders are watching whether the stock can hold the $23.30 area it tested Tuesday and reclaim the $24 level that marked Monday’s close. The June high near $26.58 remains the key upside reference point for longer-term charts.
